Foster City, CA – Gilead Sciences, Inc. (NASDAQ:GILD), a biotechnology company with a market capitalization of $115.7 billion, saw its Chief Financial Officer Andrew D. Dickinson sell shares in the company, according to a recent SEC filing. On December 16, Dickinson sold 8,500 shares of Gilead common stock at a price of $91.96 per share, totaling approximately $781,660. The stock has shown remarkable strength, gaining over 45% in the past six months according to InvestingPro data. This transaction was executed under a pre-established Rule 10b5-1 trading plan, which Dickinson adopted on August 29, 2024. Following this sale, Dickinson retains ownership of 132,373 shares in the company. Currently trading near its 52-week high with a solid 3.35% dividend yield, Gilead maintains a GREAT financial health score according to InvestingPro's comprehensive analysis, which offers 10+ additional insights and a detailed Pro Research Report for deeper understanding of the company's fundamentals.
In other recent news, biotechnology company Gilead Sciences Inc . has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for its drug Trodelvy, aimed at treating a specific form of lung cancer. This follows positive results from the Phase 2 TROPiCS-03 study, which evaluated Trodelvy as a second-line treatment for adult patients with extensive-stage small cell lung cancer. Gilead also plans to initiate a Phase 3 clinical trial to further investigate Trodelvy's efficacy in patients with ES-SCLC.
Additionally, Gilead Sciences has entered into strategic collaborations with Terray Therapeutics and Tubulis. The partnership with Terray will leverage Terray's AI-driven tNova drug discovery platform to identify therapeutic candidates across multiple disease targets. The agreement with Tubulis aims to develop an antibody-drug conjugate for solid tumor treatment.
Gilead also received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for seladelpar, a treatment for primary biliary cholangitis. This follows a successful Phase 3 trial.
Analysts from Bernstein SocGen Group and Deutsche Bank (ETR:DBKGn) maintained their Outperform and Hold ratings for Gilead, respectively. These recent developments illustrate Gilead's ongoing commitment to HIV treatment and prevention, as well as its potential for growth and profitability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.